S-1: Shuttle Pharma Files S-1 for Resale of 1.18M Shares

Shuttle Pharmaceuticals Holdings, Inc. filed an S-1 registration statement for the resale of 1,180,877 shares of common stock by a selling stockholder, stemming from a recent private placement.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell 1,180,877 shares of common stock.
• The shares consist of 21,924 outstanding shares and 1,158,953 shares issuable upon exercise of pre-funded warrants.
• These securities were issued to an accredited investor, Alternative Investment Capital Inc., in a private placement that closed on June 24, 2025.
• The purchase price for the private placement was $3.60 per share or $3.599 per pre-funded warrant, with warrants exercisable at a nominal price of $0.001.
• The company will not receive any proceeds from the sale of these shares by the selling stockholder.
• Shuttle Pharma is a discovery and development stage pharmaceutical company focused on novel cancer therapies, particularly radiation therapy.
• Its lead product candidate, Ropidoxuridine, is currently in a Phase II clinical trial for brain cancer patients undergoing radiation therapy, which commenced in October 2024.
• The company's auditor, Forvis Mazars, LLP, included an explanatory paragraph in their report regarding substantial doubt about the company's ability to continue as a going concern for the fiscal year ended December 31, 2024.

Sentiment

Score: 4

Explanation: The filing is primarily for a resale offering, not a financial performance update. While it highlights ongoing clinical development, the significant 'going concern' warning from the auditors and the fact that the company receives no proceeds from this specific resale are notable negatives. The recent private placement provided capital, but this S-1 does not. The overall sentiment is cautious due to financial viability concerns despite clinical progress.

Positives

• Ropidoxuridine is progressing, having completed Phase I and commenced Phase II clinical trials for brain cancer patients undergoing radiation therapy in October 2024.
• The FDA approved the clinical trial for Ropidoxuridine and provided recommendations to expand it, which the company agreed to, indicating regulatory engagement.
• The company has completed its radiation biomarker project and health disparities project, with plans for clinical validation and potential commercialization of Ropidoxuridine as a radiation sensitizer.

Negatives

• The company will not receive any proceeds from the sale of the 1,180,877 shares by the selling stockholder, limiting direct capital infusion from this filing.
• The independent registered public accounting firm, Forvis Mazars, LLP, included an explanatory paragraph in their report indicating substantial doubt about the company's ability to continue as a going concern.
• The sale of a substantial amount of common stock by the selling stockholder in the public market, or the perception of such sales, could adversely affect the market price of the company's common stock.

Risks

• An investment in the company's securities involves a high degree of risk.
• Sales of substantial amounts of common stock by the selling stockholder in the public market could adversely affect the market price of the common stock.
• The company cannot predict if and when the selling stockholder may sell their shares in the public market.
• There is substantial doubt about the company's ability to continue as a going concern, as noted by the independent auditors.

Future Outlook

The company is proceeding with plans for clinical validation and potential commercialization of Ropidoxuridine as a radiation sensitizer. It continues research and development efforts to advance Ropidoxuridine clinical testing and improved drug formulation, and to advance HDAC6 inhibitor (SP-2-225) preclinical development and explore the application of the PC-RAD Test.

Management Comments

• Our goal is to extend the benefits of cancer treatments by leveraging insights into cancer therapy with surgery, radiation therapy, chemotherapy and immunotherapy.
• We believe that our product candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Industry Context

Shuttle Pharmaceuticals operates in the highly competitive and capital-intensive pharmaceutical industry, specifically focusing on oncology and radiation therapy. Its strategy of developing radiation sensitizers aims to improve the efficacy and safety of existing cancer treatments like radiation therapy, a common approach in cancer care. The development of predictive biomarkers (PC-RAD Test) aligns with the broader industry trend towards personalized medicine and precision oncology.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The company's CEO purchased $250,000 of notes and warrants in the October 2024 senior secured convertible note warrant offering.
• Promissory notes were issued to Anatoly Dritschilo on September 4, 2024, and previously on December 1, 2020, with amendments on January 25, 2022, and July 29, 2022.
• A promissory note was issued to Joy Dritschilo on December 1, 2020, with amendments on January 25, 2022, and July 29, 2022.

Stakeholder Impact

• Shareholders: Potential dilution and downward pressure on stock price due to the resale of a large block of shares by the selling stockholder. The 'going concern' warning poses a significant risk to shareholder value.
• Investors (Selling Stockholder): The filing enables the selling stockholder to monetize their investment from the recent private placement.
• Employees: The 'going concern' warning could create uncertainty regarding job security and the long-term stability of the company.
• Creditors: The 'going concern' warning indicates increased risk regarding the company's ability to meet its financial obligations.

Next Steps

• The selling stockholder may sell or otherwise dispose of the registered shares in various ways and at varying prices on the Nasdaq Capital Market or other trading facilities.
• The company will continue its research and development efforts to advance Ropidoxuridine clinical testing and improved drug formulation.
• The company will continue preclinical development of HDAC6 inhibitor (SP-2-225).
• The company plans to proceed with clinical validation and potential commercialization of Ropidoxuridine as a radiation sensitizer.

Key Dates

Recommendation

The S-1 filing primarily facilitates the resale of shares by a single large investor, from which the company receives no proceeds. This, combined with the explicit 'substantial doubt about the company's ability to continue as a going concern' from its independent auditors, signals significant financial instability and risk. While there is ongoing clinical development, the fundamental financial health is severely compromised. The potential for a large block of shares to enter the market from the selling stockholder could also exert downward pressure on the stock price. For a seasoned investor, these factors collectively point to a high-risk investment with significant downside potential, warranting a 'sell' recommendation to mitigate exposure.

Keywords

Shuttle Pharmaceuticals, S-1 filing, SEC filing, resale offering, common stock, pre-funded warrants, private placement, cancer therapy, radiation therapy, Ropidoxuridine, Phase II clinical trial, biotechnology, pharmaceuticals, going concern, SHPH, Nasdaq Capital Market